Drugs / briakinumab
briakinumab
also known as
ABT-874 · A-796874.0 · ABT-874 Briakinumab · BSF 415977 · J-695 BSF-415977 LU-415977 WAY-165772 A-796874.0 · J695 · LU 415977 · Ozespa · +1 more
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01260844 | Apr 2011 → ? | psoriasis | Abbott | Withdrawn | No outcome recorded |
| Phase 1 | NCT00870948 | Jan → Apr 2009 | — | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00007163 | Dec 2000 → Nov 2002 | Crohn disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00562887 | Nov 2007 → Apr 2010 | Crohn disease | Abbott | Terminated | No outcome recorded |
| Phase 2 | NCT00086671 | Apr 2004 → Nov 2006 | multiple sclerosis | AbbVie | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT00710580 | Jul 2008 → Apr 2009 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00691964 | May 2008 → Mar 2009 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00679731 | Apr 2008 → Nov 2009 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00626002 | Feb 2008 → Oct 2011 | psoriasis | AbbVie | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00292396 Comparator | Nov 2005 → Apr 2008 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00570986 Comparator | Nov 2007 → Jun 2009 | psoriasis | AbbVie | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | briakinumab | “BACKGROUND: Briakinumab is a monoclonal antibody against the p40 molecule shared by interleukin-12 and interleukin-23, which is overexpressed in psoriatic skin lesions.” PMID 22029980 ↗ Oct 2011 |
| Known as | A-796874.0 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742995 ↗ |
| Known as | ABT-874 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00086671 ↗ |
| Known as | ABT-874 Briakinumab | “ABT-874 Briakinumab” NCT01260844 ↗ |
| Known as | BSF 415977 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742995 ↗ |
| Known as | J-695 BSF-415977 LU-415977 WAY-165772 A-796874.0 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742995 ↗ |
| Known as | J695 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00007163 ↗ |
| Known as | LU 415977 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742995 ↗ |
| Known as | Ozespa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742995 ↗ |
| Known as | WAY-165772 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742995 ↗ |
| Action | Inhibit | “J695 is an antibody that is identical to a human antibody but chemically changed so that it can attach to and eliminate an inflammatory chemical made by the body called...” NCT00007163 ↗ |
| Modality | Monoclonal antibody | “The purpose of this study is to evaluate the safety of and the clinical response to a human monoclonal anti-interleukin-12 antibody (J695) administered to patients with Crohn's disease.” NCT00007163 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT00007163 ↗ |